Mutations in epigenetic pathways are common oncogenic drivers. Histones, the fundamental substrates for chromatinmodifying and remodelling enzymes, are mutated in tumours including gliomas, sarcomas, head and neck cancers, and carcinosarcomas. Classical 'oncohistone' mutations occur in the N-terminal tail of histone H3 and affect the function of polycomb repressor complexes 1 and 2 (PRC1 and PRC2). However, the prevalence and function of histone mutations in other tumour contexts is unknown. Here we show that somatic histone mutations occur in approximately 4% (at a conservative estimate) of diverse tumour types and in crucial regions of histone proteins. Mutations occur in all four core histones, in both the N-terminal tails and globular histone fold domains, and at or near residues that contain important post-translational modifications. Many globular domain mutations are homologous to yeast mutants that abrogate the need for SWI/SNF function, occur in the key regulatory 'acidic patch' of histones H2A and H2B, or are predicted to disrupt the H2B-H4 interface. The histone mutation dataset and the hypotheses presented here on the effect of the mutations on important chromatin functions should serve as a resource and starting point for the chromatin and cancer biology fields in exploring an expanding role of histone mutations in cancer.
T he fundamental repeating subunit of chromatin is the nucleosome, a histone octamer that is wrapped by 147 base pairs of DNA 1 . The density and positioning of nucleosomes sterically determine the ability of cellular machinery to access the genome (Fig. 1a ). Consequently, chromatin structure has a crucial role in diverse processes including activating or repressing transcription to control functions such as cell fate, the cell cycle, and DNA damage repair 2 .
A critical component of chromatin-mediated regulation uses histone post-translational modifications (PTMs), in which histones integrate cellular signals to choreograph chromatin-dependent functions 3, 4 . Given the regulatory role of chromatin for all DNA-templated processes, it is not surprising that the protein machinery that 'writes' , 'reads' and 'erases' these histone marks is frequently altered in cancer, and in many cases these mutations are oncogenic drivers or contributors to tumour progression 5 . Mutations in the histones themselves have also recently been linked to cancers, namely the discovery that mutations in histone H3 occur with high genetic penetrance within rare paediatric gliomas and sarcomas [6] [7] [8] (Fig. 1b) .
These mutations, some of which act in a dominant fashion, have been deemed 'oncohistones' and include H3(K27M), which was identified in 78% of diffuse intrinsic pontine gliomas, as well as H3(G34V/R), which also occurs in paediatric glioblastomas 6, 8 . Among sarcomas, the histone H3 variant H3.3 is mutated at Lys36 (H3.3(K36M)) in 95% of chondroblastomas and at Gly34 (H3.3(G34W/L)) in 92% of giant cell tumours of the bone 7 . Oncohistones have also been observed in diffuse large B-cell lymphomas (histone H1), head and neck cancers (H3(K36M)), and in carcinosarcomas (H2A and H2B) [9] [10] [11] . A notable feature of these founding oncohistone mutations is their location at or near key regulatory PTMs in the histone tails, suggesting that they might disrupt the reading, writing, and/or erasing of these marks 12 . Work performed in several laboratories, including ours, demonstrates that the H3(K27M) mutation found in gliomas acts as a dominant-negative inhibitor of the EZH2 writer subunit of the PRC2 complex, leading to a loss of transcriptional silencing through a global reduction in H3K27 trimethylation (H3K27me3) 12, 13 .
The H3(K36M) mutation leads to a global loss of H3K36 di-and trimethylation and also increases levels of H3K27me3, which at intergenic regions promotes the recruitment of the H3K27me3 reader complex, PRC1, away from gene-associated H3K27me3 14, 15 . This aberrant recruitment leads to de-repression of Polycomb-regulated genes, blocks mesenchymal differentiation, and is sufficient to promote a sarcoma-like tumour in a mouse xenograft 14 . Notably, the H3(K36M) oncogenic driver mutation occurs at a high frequency in chondroblastomas (a tumour type with a low tumour mutation burden), but only rarely in head and neck squamous cell carcinomas (a tumour type with a high tumour mutation burden) 7, 10, 16 . Thus, the tumour type frequency of a histone mutation is not necessarily a clear predictor for biological importance.
The emerging oncohistone field raises the question of whether histone mutations exist in other cancers, and if so, whether those mutations are confined to the histone tails at or near known PTM sites, as in the current model. Thus, as a hypothesis-generating effort, we sought to catalogue and characterize the landscape of missense histone mutations across several cancer types. The mutation data reported here are available through cBioPortal (https://bit.ly/2GXH5Ve) as an interactive interface in addition to Supplementary Table 1 . We analysed this dataset to propose hypotheses and potential mechanisms that underlie the role of these oncohistones in altering chromatin structure and function, potentially contributing to the development of the tumours in which they are observed.
Analysis of both publicly available tumour sequencing databases and previously unreported data from the Memorial Sloan Kettering internal sequencing effort (MSK-IMPACT) revealed a total of 4,205 histone missense mutations in 3,143 samples from 3,074 unique patients across 183 specific tumour types (Supplementary Tables 1 and 2) . Histone mutations were identified in all core histone families and 598 samples contained several histone mutations (Extended Data Fig. 1 ).
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In total, 1,039 unique patients were identified in the MSK-IMPACT clinical sequencing cohort, with the remainder found in 98 published studies available through cBioPortal (Supplementary Table 2 ). In the MSK-IMPACT database, which we note currently includes less than one-third of histone genes, histone missense mutations are nonetheless identified in 3.8% of tumour samples. This is approximately the same prevalence as somatic mutations in a number of cancer-associated genes in the same cohort, including BRCA2, TET2, SMAD4 and NOTCH1. Because histone mutations are distributed over dozens of histone genes, we suggest that they might lack visibility in rank-ordered lists of individual genes often reported in tumour sequencing studies. This may contribute to the relative lack of emphasis on histone mutations in past studies despite a notably high mutation rate.
Identifying known oncohistones and new Lys mutants
To generate hypotheses about the functional role of these histone mutations, we conducted subsequent analysis on samples with a tumour mutation burden (TMB) of ≤10 mutations per megabase (Mb) ( Supplementary Table 3 ) (unless otherwise specified) to mitigate confounding effects from highly mutated tumours. Above a threshold of 10 mutations per Mb, the number of additional captured mutations at H3 residues K27, G34 and K36 decreases markedly, which supports the use of this specific cut-off (Extended Data Fig. 2 ). This refined dataset includes 1,921 tumour-associated histone mutations, many of which are at relevant tumour allele frequencies and occur across both common and rare tumour types (Extended Data Fig. 1 ).
Importantly, this analysis re-identified known oncohistone mutations including H3(K27M) and H3(G34R/V) in gliomas, H3(G34W) in osteosarcoma, and H3(K36M) in head and neck cancers ( Fig. 2a and Supplementary Table 3 ). Within histone H3, there are several residues, such as E105, E97 and R26, that are mutated at similar rates to the known oncohistones ( Fig. 2b ). We also observed the original set of oncohistones in tumour types in which they have not been previously appreciated. This includes H3(K27M) in melanoma and acute myeloid leukaemia, H3(G34V) in ovarian cancer, and H3(K36M) in melanoma, bladder and colorectal cancer. Thus, known driver mutations in histones, which occur at a high frequency in rare cancers, also exist at a lower frequency in more common cancers.
In keeping with the pattern of lysine mutations previously observed in oncohistones, we note similar mutations at H3 Lys4: out of a total of 9 mutations at this site, 8 were a K4M/I substitution. One K-to-M/I mutation was also observed at H3 K18 and at H4 K12, raising the possibility that the functional effects associated with known K-to-M/I changes (that is, creation of a substrate-derived methyltransferase inhibitor) may extend to additional contexts 12 . Beyond the K-to-M/I model, we also observe new lysine mutation patterns. For instance, in H2A, 10 out of 12 mutations at K74 and K75 are lysine-to-asparagine mutations. Whether the frequency of K-to-N mutagenesis indicates a functional importance akin to K-to-M mutations remains to be determined.
Mutations occur in N-terminal and globular domains
Similar to the better studied oncohistones, many of the more prevalent point mutations within any given core histone family involve the N-terminal tail domains and occur at or near the site of known PTMs ( Fig. 2a and Extended Data Figs. 7, 9) . For instance, R26 of H3 (19 mutations) is among the most commonly mutated residues in our dataset and is adjacent to K27 of H3 (18 mutations) ( Table 1 ). This suggests that these N-terminal tail mutations may influence the function of the chromatin writing, reading or erasing machinery that operates at or nearby those residues, which is consistent with the paradigm established by H3(K27M) and H3(K36M).
Notably, 4 out of 5 of the most commonly mutated residues are in a globular domain: E105 of H3 (26 mutations), E76 of H2B (24 mutations), E97 of H3 (22 mutations), and E113 of H2B (21 mutations) ( Table 1 and Extended Data Fig. 7 ). A similar trend is observed within each core histone family ( Fig. 2b ). Across all tumour types, mutations in the globular domain of H3 are observed more frequently than those in N-terminal tail, which include the well-characterized K27M and K36M mutations. In H4, the highest frequency mutations, R3C, L49F, S1C and K79N, involve both the N-terminal tail and its globular domain ( Fig. 2b) . This raises the possibility that histone mutations in tumours may have effects beyond perturbation of PTM-associated functions.
Tumour type-specific mutation trends
To explore the pattern of histone mutations between cancer types, we performed unsupervised hierarchical clustering of our dataset without using TMB cut-offs, as this could bias the analysis against tumour types with generally higher mutation rates (Extended Data Figs. 3-7). As expected, in many cases mutations at specific residues occur independently of cancer type. However, there are also instances of differential clustering. For instance, the mutational pattern of H3 residues in pancreatic cancer appears to be different from that of cervical cancer (Extended Data Fig. 3 ). Conversely, we also define clusters of mutations between cancer types, including shared H2B E76 mutations in bladder and cervical cancer, and H2A E121 mutations in bladder, breast, and head and neck cancer (Extended Data Figs. 5, 6). Furthermore, there is a distinct cluster of four different haematological malignancies defined by mutations at H3 S86 (Extended Data Fig. 3 ). Together, these observations raise the intriguing possibility of a rare lineage preference for specific point mutations within histone families.
SWI/SNF-independent mutations
Classic studies in yeast identified histone H3 and H4 mutants that abrogate the need for the SWI/SNF remodelling complex in regulating gene expression 17 . These so-called switch-independent (Sin − ) mutations cluster in the globular domains of histone H3 (residues 105-118) and histone H4 (residues 43-45) ( Fig. 3a) . One of the Sin − mutations, H3(E105K) (which is conserved from yeast to humans), occurs at the most commonly mutated residue in the dataset, and H3(E105K/Q) has been annotated in cBioPortal as a three-dimensional hotspot mutation based in part on a computational method for modelling mutations on structural data 18 . Additional yeast H3 Sin − mutations occur at H3 residues R116 and T118, which are also mutated in tumours. With regard to histone H4, there are six mutations at R45, including H4(R45C), which is a known yeast Sin − mutant 17 . Notably, H4(R45C)-containing nucleosomes have been shown to abolish higher order chromatin folding 19 . Thus, the finding of tumour mutations corresponding to the yeast Sin − mutants raises the hypothesis that they may disrupt chromatin folding and DNA packaging into nucleosomes. Given the wellestablished role of the SWI/SNF complex in regulating gene expression, these mutations may also have a role in oncogenesis through aberrant expression of oncogenes and/or disrupting developmental programs 20 . Along this line, we note that subunits of mammalian SWI/SNF subunits are mutated at relatively high frequency in a large number of human cancers 21 . Whether Sin − patch oncohistone mutations act to enhance or suppress mutations in SWI/SNF subunits in these cancers remains to be determined.
Acidic patch mutations
We observed frequent mutations within a nucleosome anchoring point commonly referred to as the 'acidic patch' formed by six H2A and two H2B residues ( Fig. 3b and Extended Data Fig. 7 ). Acidic patch mutations at residues E113 of H2B, and E92 and E56 of H2A occur at high frequencies for their respective histone families, and E113 of H2B is the fifth most common site of mutations in the dataset. Notably, H2A(E56K/Q) mutations were previously reported in human uterine and ovarian carcinosarcomas and are now reported in our dataset in non-small-cell lung cancer, renal cell carcinoma, small-cell lung cancer, head and neck cancer, pancreatic cancer, and rectal cancer 11 . Given the important function of the negatively charged acidic patch surface, tumour-associated acidic patch mutations are proposed to affect several essential biological processes including chromatin condensation and folding, nucleosome remodelling, cell division, transcriptional silencing, and DNA damage repair 22 . In fact, several of the residues mutated in our dataset, including H2A residues E61, D90 and E92, were shown to impair chromatin remodelling by ISWI 23 . Because acidic-patch-dependent processes are critical for cell identity, differentiation and genomic and epigenomic integrity, acidic patch mutations may promote oncogenesis by disruption of one or more of those pathways.
Mutations that potentially alter nucleosome structure
Mutations within the globular core domain of the histones have the potential to affect three-dimensional structure. With this in mind, we created a proximity plot based on the nucleosome structure and an enriched set of histone mutations with a residue-specific mutation count ≥2.5-fold the median count/residue in each histone family ( Fig. 3c and Extended Data Fig. 8 ). Remarkably, many of the most highly mutated residues, although quite distant in primary amino sequence, are close in space within the folded nucleosome structure. This raises the intriguing possibility that several mutations at distinct histone sites may functionally converge, either to perturb the functionality of PTMs in the immediate vicinity (Extended Data Fig. 9 ) or to directly disrupt the structure of the nucleosome (Extended Data Fig. 10 ). H2B residue E76, for example, lies at the tetramer-dimer interface between H2B and H4 and engages with residues R92 and D68 of H4 in a hydrogenbonding network that would be abolished by H2B(E76K/Q) mutations (Fig. 3d) . Indeed, recent work has shown that the H2B(E76K) mutation destabilizes nucleosomes and perturbs the local structural arrangement of H4 residue R92 24 , supporting our hypothesis that mutations at H4 residues R92 and D68 may have similar functional effects. Notably, E76 is the most highly mutated residue in the H2B family, and D68 and R92 are the second and fifth most mutated residue in the H4 family, respectively (Extended Data Fig. 7 ). In addition, a nearby salt bridge between E71 of H2B and K91 of H4 at the same interface is disrupted by acetylation and ubiquitylation of H4 K91, affecting chromatin assembly and DNA damage repair [25] [26] [27] . Germline mutations at K91 of H4 (H4(K91R/Q)) were recently found to cause a severe developmental syndrome 28 . In our dataset, E71 is the fifth most mutated residue in H2B, demonstrating a marked convergence of cancer mutation frequency onto this portion of the H2B-H4 interface.
Continuing with the theme of structural perturbations, we note there are several cases in which a glycine or proline residue is introduced into the globular domain of the histone, for example at H2A R29 and H4 R39. Alterations of this type are expected to disrupt the α-helical secondary structure of the histone fold. α-carbon distance between 3.8 and 7.6 Å, and grey lines indicate 7.6 to 11.4 Å. Intra-molecular proximities are indicated by coloured lines and only select residues are labelled for clarity of display. d, The H2B-H4 interface is mediated by hydrogen-bonding between H2BE76, H4D68 and H4R92, as well as a salt bridge between H2BE71 and H4K91. These residues all exhibit high mutational frequency, with the exception of H4K91. e, Glutamic acid (Glu) residues are frequently mutated to lysine (Lys) or glutamine (Gln), which can serve as substrates for acetylation or function as acetyl mimics, respectively. LysAc, lysine acetylation.
AnAlysis REsEARCH

Candidate neomorphs
Another notable pattern is that glutamic acid residues are the second most mutated in our study and are frequently substituted to lysine (47% of cases) or glutamine (34% of cases) ( Fig. 2a and Extended Data Fig. 7 ).
We hypothesize that these mutations may function as neomorphs in which the ectopic lysine could be post-translationally modified, or in which the glutamine functions as an acetyl-mimic to recruit reader complexes aberrantly (Fig. 3e) . That said, we recognize that the mutation patterns reported here may well be influenced by specific mutagens, nucleotide composition, codon biases, chromosomal position, and tissue type. Nonetheless, we look forward to experimental testing of this hypothesis.
Mutations identified by 'a posteriori' approaches
Although some candidates for histone driver mutations may be hypothesized a priori, as above, there may also be less intuitively apparent yet functionally important mutations within the dataset. Given that tumours typically contain two to eight driver mutations, focusing on histone mutations occurring in a low mutational background may be useful in refining the list of candidate histone driver mutations 29 . Thus, we analysed the subset with a TMB ≤ 2 mutations per Mb ( Supplementary Table 4 ). Notably, among the histone mutations seen in the context of a low TMB are the known H3(K27M) and H3(G34W) oncohistones (although not H3(K36M)), suggesting that a low TMB cut-off captures a subset of functionally relevant histone mutations. Other mutations in this subset include H3(E105K/Q), mutations at H3 N-terminal residues at or near PTM sites including R2, R8, K18 and R26, as well as residues in the acidic patch such as H2A residues E56, E64, E9, and E92 and H2B residues E105 and E133. Notably, this low TMB threshold list also includes mutations without a clear functional correlation, raising questions regarding as yet unrecognized function. These types of mutation are likely to serve as an excellent starting point for future mechanistic investigations.
As an additional methodology to identify mutations that are potentially functional, we applied a previously published computational strategy to identify three-dimensional clusters of mutations 18 . This approach identified regions of all four core histones, which contain potential functional mutations, especially those that occur at lower frequency ( Table 2 ). These regions include the portions of the H3 Sin − patch and PTM-rich segments of the H3 and H4 tails, which bolsters the argument that mutations at or near the sites of regulatory PTMs may have functional importance. This analysis also highlights stretches of the H2A and H2B globular domains that would not have been recognized otherwise but are significantly mutated. We suggest that mutations occurring in those regions warrant further investigation into functional consequences.
'Missing' mutations
Finally, some residues are notably mutationally silent in the dataset, even taking into account tumours with high TMB thresholds (Supplementary Table 1 ). For example, in H2A there are no mutations at F25, A45, L85, V107, L115 and T120 (exclusive of variant sequences at these positions). The relative underrepresentation of mutations at these positions leads us to propose that these residues, and similarly underrepresented residues in other core histones, may contain important functions that are lost when mutated, thereby causing a fitness disadvantage during tumour development. This indicates that there may also be a dependency of these tumour cells on the machinery that writes, erases and reads the post-translational marks at or near these residues. Targeting this machinery with small molecules could represent a previously unrecognized therapeutic opportunity.
Histone mutations in the context of chromatin
We have previously hypothesized that the combinatorial nature of histone PTMs and the physiological context of histones within a nucleosomal polymer invoke unique biological consequences 3, 30 . Thus, we favour the view that histone mutations can perturb important chromatin-mediated processes, even at lower concentrations than normal histones. For example, incorporation of a defective polymer subunit (that is, a histone with a single amino acid substitution) acting as a nucleation site, could lead to amplified effects on chromatin due to both the biophysical and functional interdependency of nucleosomal subunits, the latter of which is attributed to the histone code 3 . Alternatively, a mutant histone may behave as an aberrant boundary element that disrupts the activity of a PTM writer, thereby impairing (either directly or indirectly) the propagation of histone marks (Fig. 4) . In support, the H3(K36M) oncohistone causes a redistribution of PRC1 by altering the balance of H3K27me3 between intragenic and genic regions 14 .
We suggest that histone mutants-by virtue of incorporation into chromatin-are primed to have dominant-negative effects on chromatin-dependent processes. This is in contrast to a hypothetical mutation in one of a dozen redundant genes for a signalling kinase, which would probably be compensated by independent functional gene products. Mis-activation and/or mis-repression Tumorigenesis Fig. 4 | A model for the effect of oncohistones on the chromatin polymer. By incorporation into the chromatin polymer, mutated histone proteins (oncohistones, in red) may cause functional effects by altering the biophysical and/or functional properties of chromatin. We propose that these effects will occur when the mutant histone is present even at low concentrations and that mutating even one of many histone gene copies can have dominant effects.
Thus, interpreting histone missense mutations using common models of cancer genetics does not necessarily account for the chromatin polymer into which mutant histone proteins are incorporated. We look forward to the development of new models for histone mutations in this context, which we hope to facilitate with the work we present here. In summary, these analyses highlight a considerably greater number of histone mutations in human tumours than had previously been recognized. Given the key role that histones have in cell fate and differentiation as the substrates for epigenetic machinery, histone mutations may cause the dysregulation of these processes, a step central to oncogenesis 31 . Although many of the mutations in the dataset may ultimately be passengers, the nature of a subset of the mutations that we analysed has enabled us to generate testable hypotheses about possible functional roles of these oncohistones in tumorigenesis. Understanding mechanisms that underlie a subset of these mutations may reveal how disrupting histone or nucleosomal function may contribute to oncogenic transformation.
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Experimental design 1. Sample size
Describe how sample size was determined.
Sample size was determined based upon the availability of studies in cBioPortal, which in the case of this study included 98 published studies as well as MSK-IMPACT data.
Data exclusions
Describe any data exclusions.
None.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
There were no measures taken beyond the quality control measures used in the sequencing studies from which the analyzed data were sourced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Samples were not allocated into experimental groups in this paper.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
As no groups were allocated, blinding was not performed. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
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